Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethoximod PK/PD in healthy subjects
NCT06361212Phase 1Completed
- Start
- Sep 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ethoximod in psoriasis (3 arms). Primary endpoints: Peak Plasma Concentration up to 64 days, Time to Peak Plasma Concentration up to 64 days and 3 more. Started Sep 2022; status: completed.
02
Drugs
ethoximod
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06361212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361212.